Neumora Therapeutics (NMRA) to Release Earnings on Tuesday

Neumora Therapeutics (NASDAQ:NMRA) is scheduled to announce its earnings results before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.38) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Neumora Therapeutics (NASDAQ:NMRA) last announced its earnings results on Tuesday, August 6th. The company reported ($0.37) earnings per share for the quarter, meeting the consensus estimate of ($0.37). On average, analysts expect Neumora Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Neumora Therapeutics Trading Down 7.2 %

Shares of NMRA stock traded down $0.84 during trading hours on Tuesday, reaching $10.87. 681,260 shares of the stock were exchanged, compared to its average volume of 708,613. Neumora Therapeutics has a 12-month low of $8.33 and a 12-month high of $21.00. The firm has a market capitalization of $1.74 billion, a price-to-earnings ratio of -4.57 and a beta of 3.92. The company’s 50-day moving average price is $12.92 and its 200-day moving average price is $11.29.

Insider Buying and Selling

In other news, CFO Joshua Pinto sold 31,642 shares of Neumora Therapeutics stock in a transaction on Monday, August 26th. The stock was sold at an average price of $11.78, for a total value of $372,742.76. Following the transaction, the chief financial officer now directly owns 154,658 shares in the company, valued at approximately $1,821,871.24. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, CFO Joshua Pinto sold 31,642 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $11.78, for a total value of $372,742.76. Following the sale, the chief financial officer now directly owns 154,658 shares in the company, valued at approximately $1,821,871.24. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Matthew K. Fust sold 14,049 shares of the business’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $17.03, for a total transaction of $239,254.47. Following the transaction, the director now owns 20,100 shares of the company’s stock, valued at approximately $342,303. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 110,538 shares of company stock valued at $1,390,513 over the last 90 days. Corporate insiders own 26.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on NMRA shares. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 target price on shares of Neumora Therapeutics in a research note on Friday, October 18th. HC Wainwright began coverage on Neumora Therapeutics in a research note on Tuesday, October 1st. They issued a “buy” rating and a $30.00 target price on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $29.00 target price on shares of Neumora Therapeutics in a research note on Wednesday, September 4th. Mizuho started coverage on shares of Neumora Therapeutics in a research note on Monday, July 8th. They issued an “outperform” rating and a $20.00 price target on the stock. Finally, JPMorgan Chase & Co. cut shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $18.00 to $15.00 in a research report on Tuesday. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.67.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.